[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lorenzo delSorbo\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100618650","phase-2-interleukin-6-guided-treatment-with-dexamethasone-or-tocilizumab-in-patients-hospitalized-with-acute-respiratory-symptoms---a-feasibility-study-100618650",false,"NCT07334379","Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study","IDENTIFY","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Presence of new onset of respiratory symptoms in the previous 14 days upon presentation at the emergency department. Respiratory symptoms are characterized by at least one of the following: cough, dyspnea, or requirement of oxygen supplementation\n3. Requirement of inpatient hospital management\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Patients with known contraindications to dexamethasone or tocilizumab, or any of their components\n3. Allergic reaction to tocilizumab or other monoclonal antibodies\n4. Patients who are using azathioprine or cyclophosphamide\n5. Active tuberculosis infection\n6. Patients who have active hepatic disease or hepatic impairment\n7. ALT or AST \\>3x upper limit of normal\n8. Neutrophil count \\\u003C1000\u002Fmcl\n9. Platelet count \\\u003C50,000\u002Fmm3\n10. Hemoglobin (Hb) below 8.5 g\u002FdL,\n11. White blood cell count (WBC) below 3000\u002Fmm3\n12. Absolute Neutrophil Count (ANC) below 2.0 x 109\u002FL\n13. absolute lymphocyte count below 500\u002Fmm3\n14. total bilirubin above ULN\n15. Triglycerides (TG) above 10 mmol\u002FL (above 900 mg\u002FdL)\n16. Serum creatinine above 1.4 mg\u002FdL in female patients and above 1.6 mg\u002FdL in male patients\n17. Patients already receiving systemic steroids, monoclonal antibodies or other immunosuppressive medications at the time of presentation\n18. Inability to comply with the regulations to avoid conception within 28 days after enrollment\n19. Admission to ICU prior to randomization\n20. Immediate need for intubation\n21. Imminent death\n22. Clinical team refusal\n23. Participation in other drug clinical trials (this criterion will be discussed with the PI)\n24. Reaching \\>72h since hospital admission\n25. Pregnancy (positive pregnancy test) or breastfeeding (which is a contraindication to tocilizumab)","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Acute hypoxemic respiratory failure (AHRF) happens when the lungs are unable to absorb enough oxygen. The bloodstream is deprived of oxygen which can eventually lead to more severe conditions like multi-organ failure (MOF) and death. AHRF accounts for over 30% of patients to critical care units, thus novel treatments are sorely needed. Research has shown that blood levels of the inflammatory biomarker Interleukin-6 (IL-6) may be a reliable marker for predicting which patients with AHRF will progress into requiring intensive care unit (ICU) admission, MOF, and eventually death. IL-6 levels were shown to reliably peak several days before MOF, ICU admission, and death. Thus, the investigators believe that by identifying patients before the peak of their IL-6 levels, they will be able to administer early treatment to prevent the patient's condition from worsening. The aim of this study is to test the feasibility of a treatment strategy for AHRF based on IL-6 measurement in patients who are admitted to hospital care with AHRF.\n\nPatients who are eligible for the study will have their plasma IL-6 levels measured over 2 days. Patients with elevated IL-6 levels will be randomized into 1 of 3 treatment groups: standard of care only, standard of care plus a single IV infusion of Tocilizumab, or standard of care plus treatment with oral Dexamethasone for 10 days. Patients will then be observed till discharge or up to 28 days, and a follow-up phone interview will be conducted 6 months of the end of the observation period.",[26],"Acute Hypoxemic Respiratory Failure","RECRUITING","2026-01-05",{"date":30,"type":31},"2026-01-12","ACTUAL",{"date":33,"type":31},"2025-10-20",{"date":35,"type":20},"2027-02-26",{"name":37,"class":38},"Lorenzo delSorbo","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":39},"100536017","prone-positioning-in-neurologically-deceased-potential-organ-donors-to-improve-donor-lung-function-and-lung-transplant-recipient-outcomes-100536017","NCT06259357","Prone Positioning in Neurologically Deceased Potential Organ Donors to Improve Donor Lung Function and Lung Transplant Recipient Outcomes","Prone Positioning in Neurologically Deceased Potential Organ Donors to Improve Donor Lung Function and Lung Transplant Recipient Outcomes (P-POD) Pilot Trial","P-POD","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Neurological determination of death at time of study entry\n3. Consent to organ donation\n4. Eligible for organ donation as confirmed by Trillium Gift of Life Network Coordinator\n\nExclusion Criteria:\n\n1. Open chest or abdominal wounds on the ventral body surface\n2. Absolute contraindication to lung transplantation on initial eligibility screening:\n\n   * Infection i. Positive HIV, HbsAg, Human T-lymphotropic virus-I\u002FII test results ii. Positive West Nile Virus (WNV PCR) test results iii. Rabies diagnosis or within the last 6 months bitten by an animal proven to have rabies iv. Active endocarditis v. Active encephalitis or meningitis of unknown etiology vi. Active disseminated tuberculosis vii. Viral hemorrhagic fever including Ebola or known exposure to person with Ebola viii. COVID-19 presumptive or confirmed positive in the last 14 days\n   * Malignancy i. Donors with active cancer (donors receiving chemotherapy or radiation therapy or palliative cancer care within the last 5 years); excluding skin and primary brain tumors and prostate cancers.\n\nii. Donors with a history of the following malignancies:\n\n* Lung Cancer\n* Choriocarcinoma\n* Breast Cancer\n* Colon Cancer within the last 10 years iii. Donors with active or past history of melanoma o Clinician decision that prone position is contraindicated",{"count":49,"type":20},40,[51],"NA","The purpose of this study is to determine the practicality of performing a future, large-scale study. The future study will look at the effect of mechanical ventilation in neurologically deceased (brain-dead) lung donors who are positioned to lay flat on their stomach (prone position), compared to donors who are positioned to lay flat on their back (supine position). The study will also look at the potential impact of prone positioning of the donor on transplant recipients of the study organs.\n\nThe investigators are doing this study because the investigators want to increase the availability of donor lungs for lung transplant. Lung transplant is a life-saving treatment for individuals with lung disease, but there are not enough donated lungs to meet demand. Researchers are looking for better ways of preventing donated lungs from becoming unsuitable for transplant. Because of this, the goal of our study is to test whether prone positioning in neurologically deceased (brain-dead) lung donors can improve donor lung function and decrease complications, potentially increasing the number of donor lungs that can be used for transplant.",[54],"Lung Transplant Failure","NOT_YET_RECRUITING","2024-12-03",{"date":58,"type":31},"2024-12-04",{"date":60,"type":20},"2025-01-02",{"date":62,"type":20},"2026-08-01",{"name":37,"class":38},""]